High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

@article{Romaguera2005HighRO,
  title={High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.},
  author={J. Romaguera and L. Fayad and Maria A Rodriguez and K. Broglio and F. Hagemeister and B. Pro and P. Mclaughlin and A. Younes and F. Samaniego and A. Goy and A. Sarris and N. Dang and Michael Wang and V. Beasley and L. Medeiros and R. Katz and H. Gagneja and B. Samuels and Terry L. Smith and F. Cabanillas},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 28},
  pages={
          7013-23
        }
}
PURPOSE To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL). PATIENTS AND METHODS This was a prospective phase II trial of rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD; considered one cycle) alternating every 21 days with rituximab plus high-dose methotrexate-cytarabine… Expand

Paper Mentions

Interventional Clinical Trial
This is a dose-escalation to determine the MTD and/or RPII for combinations of ibrutinib (PCI-32765) plus lenalidomide/rituximab in patients with relapsed/refractory mantle cell… Expand
ConditionsMantle Cell Lymphoma
InterventionDrug
Interventional Clinical Trial
This is a Phase I/II multicenter, open-label, dose-escalation study of rituximab, bortezomib, and lenalidomide in the first-line or second-line treatment of patients with Mantle Cell… Expand
ConditionsMantle Cell Lymphoma
InterventionDrug
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
  • B. Kahl, W. Longo, +8 authors H. Bailey
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
  • O. Howard, J. Gribben, +4 authors M. Shipp
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.
Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?
Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis
...
1
2
3
4
5
...